Grifols, S.A. (BME:GRF)
Spain · Delayed Price · Currency is EUR | Market Cap | 6.68B |
| Revenue (ttm) | 7.52B |
| Net Income (ttm) | 372.72M |
| Shares Out | 680.51M |
| EPS (ttm) | 0.55 |
| PE Ratio | 20.09 |
| Forward PE | 11.97 |
| Dividend | 0.30 (2.73%) |
| Ex-Dividend Date | Aug 11, 2025 |
| Volume | 336,287 |
| Average Volume | 1,093,616 |
| Open | 10.93 |
| Previous Close | 10.99 |
| Day's Range | 10.93 - 11.03 |
| 52-Week Range | 7.32 - 13.70 |
| Beta | 1.19 |
| RSI | 56.76 |
| Earnings Date | Feb 25, 2026 |
About Grifols
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an... [Read more]
Financial Performance
In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.
Financial StatementsNews
Grifols: Solid Q3 Execution, But Cash Conversion And 2026 Risks Keep Us Neutral
Revenue momentum remains strong and EBITDA execution is intact, but FX-adjusted guidance implies Q4 slightly below consensus and cash conversion continues...
Grifols Secures FDA Approval To Launch Fesilty In US In First Half Of 2026
(RTTNews) - Biotest AG, Friday announced that its parent company Grifols, S.A. (GRFS) has received approval from the U.S. Food and Drug Administration for Fesilty, a human fibrinogen product developed...
Grifols: Positive/Neutral Scenario Posits An Upside
Grifols, S.A. earns a Buy rating after strong Q3 '25 results, growth forecasts, and a restored dividend. Click for this GRFS stock update.
Grifols (GRFS): Analyst Maintains Neutral Rating, Lowers Price Target | GRFS Stock News
Grifols (GRFS): Analyst Maintains Neutral Rating, Lowers Price Target | GRFS Stock News
Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript
Q3 2025 Grifols SA Earnings Call Transcript
Q3 2025 Grifols SA Earnings Call Transcript
Grifols, S.A. 2025 Q3 - Results - Earnings Call Presentation
Top Biotech Stocks Riding The Rally
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock pric...
Grifols (GRFS) Sees Revenue Boost from Biopharma Sector
Grifols (GRFS) Sees Revenue Boost from Biopharma Sector
4 Best Value And Growth Stocks (Yes, They Can Coexist)
The current market is all about momentum, but investors don't need to buy overpriced high-growth stocks to participate in gains. If you dig deep enough, you can find undervalued stocks with growth pot...
Are Investors Undervaluing Grifols (GRFS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
Spanish court summons Gotham City founder in Grifols share price probe
Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Grifols: Significant Upside Likely Materializing
Blood donors surprised Canadian plasma products being sold abroad
Canadian Blood Services is selling blood donation byproducts to the multinational pharmaceutical company Grifols SA, which is using it to make medications for sale abroad.
Grifols S.A. declares $0.1404 dividend
Grifols: Reassuring Evidence, Still On The Sidelines
Grifols revises forecasts upward after strong Q1, targeting €10B sales and €2.9B EBITDA. Click here to read my analysis of GRFS stock.
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and...
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF...
Grifols lawsuit against Gotham City to proceed after New York court ruling
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on...
Grifols: If This Works Out, It Has Massive Upside
Grifols S.A. reports Q1 results
Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript
Grifols says on course to meet 2025 outlook as net profit triples
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.